<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792023</url>
  </required_header>
  <id_info>
    <org_study_id>FIT-Iron deficiency anemia</org_study_id>
    <nct_id>NCT02792023</nct_id>
  </id_info>
  <brief_title>Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT)</brief_title>
  <acronym>IDAFIT</acronym>
  <official_title>Usefulness of Fecal Immunochemical Test in the Diagnosis Algorithm of Iron Deficiency Anemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to test whether the immunochemical fecal occult blood test (FIT) for
      colorectal cancer (CRC) helps to prioritize patients with iron deficiency anemia for
      colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (two centers), prospective study to test the accuracy of FIT for CRC
      detection in patients with severe IDA and its potential value for prioritizing colonoscopy.

      An appointment with a gastroenterologist will be scheduled for patients with IDA referred for
      upper gastrointestinal endoscopy or colonoscopy. The gastroenterologist will check the
      inclusion and exclusion criteria. Eligible patients will sign the informed consent to carry
      out the following procedures:

        1. Blood analysis to rule out celiac disease (anti-transglutaminase IgA antibodies and
           IgA).

        2. A quantitative fecal immunological test (FIT: OC-Sensor ®) will be provided.

        3. An appointment for colonoscopy and gastroscopy will be provided after completion of the
           FIT in all patients. During gastroscopy, duodenal biopsies from the second portion of
           the duodenum and duodenal bulb will be taken to rule out celiac disease. Biopsies from
           the stomach will be also taken to assess helicobacter pylori infection.

        4. In patients with severe anemia colonoscopy and upper endoscopy will be prioritized (&lt;20
           days) (primary outcome).

        5. Patients with colonoscopy and gastroscopy without significant lesions, will be scheduled
           for the performance of a capsule endoscopy.

        6. Endoscopists will be blind for the FIT results.

        7. the following information will be collected: consumption of acetylsalicylic acid, non
           steroidal anti inflammatory drugs, oral anticoagulants, corticosteroids and proton pump
           inhibitors (PPI). In the case of patients receiving treatment with PPIs, they will be
           removed 15 days before the completion of the FIT and not resumed until the performance
           of the upper endoscopy.

      The hypothesis of the study is that one-time FIT is a useful tool for increasing the
      efficiency of colonoscopy and can be used to prioritize outpatient colonoscopy in patients
      with IDA. In order to calculate the sample size required for the study, the investigators
      have assumed that FIT is positive in 25% of cases with iron deficiency anemia and 20% of them
      would have an advanced colorectal neoplasia at colonoscopy whereas only 10% of advanced
      colorectal neoplasias would be found in the remaining 75% patients with a negative FIT.
      Considering a type I error (alpha) of 5%, a power of 80% and a percentage of losses of 15%,
      550 patients will be necessary to include. The investigators estimate that approximately 15%
      of these patients (n=83) will have severe anemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value)</measure>
    <time_frame>one year</time_frame>
    <description>In order to calculate the positive predictive value, the number of patients with events (colorectal cancers) will be divided among the number of positive immunochemical fecal tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with a significant lesion among those with a positive immunochemical fecal test (Positive predictive value) after the colonoscopy and after the upper endoscopy</measure>
    <time_frame>one year</time_frame>
    <description>In order to calculate the positive predictive value, the number of patients with a significant lesion (i.e. colorectal cancer, advanced adenoma, inflammatory bowel disease, angiodysplasia, gastric cancer, watermelon stomach, gastric/duodenal ulcer, ampulloma, erosive gastritis/duodenitis) will be divided among the number of positive immunochemical fecal tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy</measure>
    <time_frame>one year</time_frame>
    <description>In order to calculate the negative predictive value, the number of patients without a significant lesion will be divided among patients with a negative immunochemical fecal test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Colonoscopy followed by upper endoscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upper endoscopy followed by colonoscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunochemical fecal occult blood test</intervention_name>
    <description>Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital</description>
    <arm_group_label>Colonoscopy followed by upper endoscopy</arm_group_label>
    <arm_group_label>Upper endoscopy followed by colonoscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants</description>
    <arm_group_label>Colonoscopy followed by upper endoscopy</arm_group_label>
    <arm_group_label>Upper endoscopy followed by colonoscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Upper endoscopy</intervention_name>
    <description>An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants</description>
    <arm_group_label>Colonoscopy followed by upper endoscopy</arm_group_label>
    <arm_group_label>Upper endoscopy followed by colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive outpatients with iron deficiency anemia (Hemoglobin &lt; 13 g/dl in males and
             12 g/dl in females) referred for upper endoscopy and/or colonoscopy.

          -  To sign the informed consent.

        Exclusion Criteria:

          -  &lt; 18 years

          -  Pregnancy

          -  Personal history of inflammatory bowel disease

          -  Gastric / duodenal ulcer or gastrointestinal neoplasia

          -  Family history of hereditary CRC (Lynch Syndrome or familial adenomatous polyposis)

          -  Rectal bleeding / hematochezia

          -  Gastroscopy / colonoscopy / endoscopy capsule in the previous 5 years

          -  Patients not candidates for endoscopic studies because a low performance status

          -  Previous abdominal surgery

          -  Refusal to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Quintero, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Carrillo, MD, PhD</last_name>
    <phone>34-922678000</phone>
    <phone_ext>34039</phone_ext>
    <email>martacarry@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Service, Huc</name>
      <address>
        <city>La Laguna</city>
        <state>S/c de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ENRIQUE QUINTERO, MD. PhD.</last_name>
      <phone>615553711</phone>
      <email>equintero@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ENRIQUE QUINTERO, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Z Gimeno García, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaida Adrián de Ganzo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David N Pérez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Carrillo Palau, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>James MW, Chen CM, Goddard WP, Scott BB, Goddard AF. Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1197-203.</citation>
    <PMID>16215432</PMID>
  </reference>
  <reference>
    <citation>Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The importance of anaemia in diagnosing colorectal cancer: a case-control study using electronic primary care records. Br J Cancer. 2008 Jan 29;98(2):323-7. doi: 10.1038/sj.bjc.6604165. Epub 2008 Jan 22.</citation>
    <PMID>18219289</PMID>
  </reference>
  <reference>
    <citation>Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012 Feb 23;366(8):697-706. doi: 10.1056/NEJMoa1108895. Erratum in: N Engl J Med. 2016 May 12;374(19):1898.</citation>
    <PMID>22356323</PMID>
  </reference>
  <reference>
    <citation>Quintero E, Carrillo M, Gimeno-García AZ, Hernández-Guerra M, Nicolás-Pérez D, Alonso-Abreu I, Díez-Fuentes ML, Abraira V. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.</citation>
    <PMID>25127679</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Alonso L, Rodríguez-Moranta F, Ruiz-Cerulla A, Lobatón T, Arajol C, Binefa G, Moreno V, Guardiola J. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test. Dig Liver Dis. 2015 Sep;47(9):797-804. doi: 10.1016/j.dld.2015.05.004. Epub 2015 May 15.</citation>
    <PMID>26055489</PMID>
  </reference>
  <reference>
    <citation>Cubiella J, Salve M, Díaz-Ondina M, Vega P, Alves MT, Iglesias F, Sánchez E, Macía P, Blanco I, Bujanda L, Fernández-Seara J. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis. 2014 Aug;16(8):O273-82. doi: 10.1111/codi.12569.</citation>
    <PMID>24456168</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Immunochemical occult blood test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

